Knowing the published side effects of these drugs itself should provide a balanced response on using these in patients which would most benefit from it
Eli Lilly is also enrolling patients in its own trial, TREASURE-CKD , to see if tirzepatide (marketed under the names Mounjaro for type 2 diabetes and Zepbound for obesity) can treat CKD in people with obesity or type 2 diabetes
Galectin Therapeutics Inc, Cirius Therapeutics Inc, Inventiva Pharma SA, Akero Therapeutics Inc and Theratechnologies Inc, are also moving their NASH therapeutic candidates into later stage clinical development, encouraged by patient outcomes, safety profiles and the hitting of key endpoints in early clinical studies
In this population, oral semaglutide 50 mg induced clinically meaningful reductions in body weight, with accompanying improvements in cardiometabolic risk factors. The study was simultaneously released at the American Diabetes Association 2023 Scientific Sessions alongside several other presentations testing oral formulations in diabetes (PIONEER PLUS) as well as a new dual glucagon (GCG) receptor and GLP-1 receptor drug, survodutide, and the triple-targeting retatrutide, which acts on GLP-1, GCG, and glucose-dependent insulinotropic polypeptide (GIP)